Securing Neuro-Privacy

**Susmit Mukherjee

Framing the claim as an argument for recognition

Brain–computer interfaces are moving from research labs into ordinary life. From low-cost headsets that promise better focus to implantable arrays that restore communication for people with paralysis, neurotechnology is beginning to mediate everyday experience. I am not claiming neuro-privacy is already a universal human right. I am arguing that democratic states should recognise and protect a distinct entitlement to control neural data. Indian constitutional doctrine supports this direction. The Supreme Court’s recognition of privacy as intrinsic to dignity and autonomy in Justice K S Puttaswamy (Retd.) v. Union of India establishes a principled foundation for treating mental and neural information as especially intimate.

What neuro-privacy should mean

By neuro-privacy I mean an individual’s authority to determine the collection, processing, retention, disclosure and deletion of information directly derived from brain activity. Neural data can be captured at very different levels of fidelity and intrusiveness. Non-invasive electroencephalography headsets sample scalp potentials. Functional near-infrared spectroscopy measures localized hemodynamic changes that correlate with neural activity. Ear-mounted and surface sensors can infer attention or affect. Implanted microelectrode arrays and ultra-thin cortical films record high-resolution activity from the brain itself. These signals differ from typical behavioural data because they can reveal mental states that people reasonably expect to keep private, including emotional reactions, intentions in formation and, in tightly controlled research settings, aspects of perceived or intended speech. That intimacy, and the risk of irreversible harm if such data is misused, justifies a tailored legal response.

The technology landscape and why risks are real

Neurotechnology already spans consumer wellness and clinical care. On the consumer side, devices like Muse, Emotiv, Neurosky and OpenBCI make EEG accessible for meditation, gaming and personal research. Their growing use and capabilities have been mapped in a recent scoping review on consumer-grade EEG devices. At the clinical end, companies such as Neuralink and Precision Neuroscience are developing implantable interfaces to restore communication and movement, including systems designed to decode speech-related neural activity. The clinical pathway involves significant oversight. The United States Food and Drug Administration’s guidance on implanted brain-computer interface devices sets expectations for non-clinical testing and study design, reflecting the safety stakes of such implants.

The privacy risks do not arise only in surgical contexts. Continuous neural streams are rich, high-dimensional signals. Machine-learning models trained on them can infer cognitive workload and affect and, in experimental settings, reconstruct elements of perceived or intended speech, as demonstrated in recent decoding research. Once such inferences become feasible outside the lab, they can be repurposed for targeted persuasion, workplace monitoring, behavioural profiling or automated decisions that affect access to services. Errors are also consequential. Misclassification of mood, attention or intent could harm people when a device drives an actuator, nudges a medical interpretation or influences a high-stakes eligibility decision. Because neural traces are persistent and subject to reinterpretation as models improve, a one-time, static consent is a poor fit for the risks. Long retention and cross-context sharing magnify the threat surface, while standard anonymization techniques struggle against re-identification when data is both distinctive and continuous.

India’s legal position: a strong constitutional core and a legislative gap

India’s constitutional jurisprudence provides a powerful anchor. Puttaswamy grounds privacy in dignity and autonomy under Article 21 and recognizes informational self-determination as part of that right. On the statutory side, the Digital Personal Data Protection Act, 2023 establishes a consent-centric baseline, sets duties for data fiduciaries, creates rights to access and deletion, provides grievance redress and establishes the Data Protection Board of India to enforce the framework. The Act, however, does not create special categories such as sensitive personal data. That was a design choice to simplify the law. In practice it leaves regulators without an explicit lever to impose heightened safeguards on neural signals that are continuous, intimate and open to future reinterpretation. That is the core legislative gap this piece addresses.

The regulatory fault line between clinical devices and consumer neurotech

Clinical neurodevices fall under the medical device regime, with the Central Drugs Standard Control Organization empowered to enforce safety and performance standards under the Medical Devices Rules, 2017. That perimeter captures high-risk implants, clinical trials and post-market surveillance. Consumer brain-computer interfaces are marketed as wellness, entertainment or productivity tools. They often sit outside medical device oversight while still collecting and transmitting neural signals. The result is a split system. Implants face stringent safety and performance review. Mass-market wearables can reach millions with minimal pre-market scrutiny of their privacy design, data retention and cross-platform sharing practices. A principled approach should not treat these device categories as opposites. It should regulate them along a risk spectrum that integrates data protection for consumer devices with safety obligations for clinically significant systems.

A practical regulatory architecture for India

A workable model should be modular, technology-aware and proportionate. First, Parliament or the Central Government under rule-making power should create a high-risk personal data class and explicitly name neural signals within it. That could be achieved either by amending the DPDP Act or by notifying a class through delegated legislation. The effect would be to require stricter processing conditions, purpose limitation, data minimization and higher penalties for misuse.

Second, consent should be dynamic and discoverable. Device firmware and companion apps should include a live consent dashboard that shows which channels are active, the purposes currently in play, the retention horizon and all third-party recipients. The dashboard should allow a person to pause collection instantly. Every change to purpose or retention should trigger a fresh, granular opt-in rather than rely on vague bundled consent.

Third, transparency must be standardized. Every device that collects or processes neural signals should include a one-page Neuro-Privacy Statement in plain language that discloses sampling rates, inference types, on-device processing versus cloud transfer, retention periods, security controls and third-party sharing. This statement should be a binding representation enforceable by the Data Protection Board. It should also be machine-readable so researchers and watchdog groups can compare products at scale.

Fourth, privacy-by-design should be a condition of market entry for implanted and clinically significant systems. Building on the medical device regime, the regulator should require encryption of neural streams at rest and in transit, authenticated firmware updates, immutable audit logs, separation of raw data from inference outputs and post-market surveillance not only for safety events but for privacy incidents and data misuse. The FDA’s BCI guidance is a helpful reference point for test design and hazard analysis that Indian regulators can adapt to local contexts.

Fifth, accountability needs a specialized forum. A Neuro-Privacy Ombudsman housed within MeitY or established as an independent statutory office could investigate complaints quickly, order product recalls, mandate corrective updates and coordinate with state police and sectoral regulators where criminal or unfair trade practices arise. Remedies must acknowledge that harms may be psychological and reputational as well as economic or bodily.

Sixth, default settings should protect by design. Raw neural streams should remain on device where feasible, with only derived metrics leaving the device. Purpose compatibility should be tightly defined so that data collected for accessibility or rehabilitation cannot be repurposed for advertising or employee monitoring without a fresh, specific and revocable consent. Retention should be short by default, with automatic deletion schedules visible in the dashboard.

Seventh, user rights should be adapted to continuous data. People should be able to download a meaningful export of their neural data and inference outputs in an open format, revoke past sharing prospectively, and see a provenance record that shows when and how an inference was generated. When inferences fuel automated decisions that significantly affect individuals, an explanation duty should apply in language a non-expert can understand.

Concrete examples that illustrate the stakes

Consider a student using a consumer EEG headband that advertises improved focus. The device streams readings to a cloud service, which pushes a productivity score to a school dashboard. The student’s readings are later reinterpreted to predict mood trends and sold, in aggregated form, to a marketing partner. Even if the data was first collected for a beneficial purpose, the combination of continuous measurement, model evolution and cross-context sharing produces risks that ordinary one-time consent cannot manage. Or consider a rehabilitation centre that uses an implantable system for a patient with paralysis. The raw neural data is backed up to a third-party cloud as part of routine maintenance. A vulnerability in the vendor’s support portal exposes a portion of the backup. The safety event might be minor. The privacy breach is not. A responsive framework must be able to mandate on-device safeguards, limit cross-context repurposing, require rapid reporting and offer redress that takes account of dignitary harm.

Comparative approaches and lessons for India

Other jurisdictions offer practice strands that India can adapt. The European Data Protection Supervisor’s TechDispatch on neurodata urges treating neural information as especially sensitive, raising the bar for consent, documentation and transparency and warning against expansive secondary use. The European approach illustrates how general data protection law can coordinate with sectoral safety rules. In the United States, device-safety oversight has evolved through the FDA’s BCI device guidance, which focuses on testing paradigms, risk analysis and patient protections in trials. For India the useful takeaway is complementarity. Robust data-protection obligations, tailored to neural signals, should sit alongside rigorous device-safety oversight. In the near term, voluntary certification marks and technical standards can bridge gaps. A BIS-hosted standard for neurodata handling and an industry Neuro-Privacy Seal could raise the floor while statutory tools mature.

Implementation without stifling innovation

It is possible to protect mental autonomy and still encourage responsible innovation. A risk-tiered approach reduces burdens for low-risk biofeedback products while placing strict requirements on devices that claim clinical benefit or collect high-fidelity streams. Sandboxes can help startups validate privacy-by-design and security claims under supervision, with clear time limits and public reporting. Procurement can drive best practice. If public hospitals and universities buy only from vendors with auditable consent dashboards, on-device encryption and short retention policies, the market will follow. Research exceptions should remain. The key is to ensure ethics review boards evaluate privacy risks alongside classical human-subject protections and that data sharing agreements bind downstream recipients to the same safeguards.

Ethics, literacy and institutional capacity

Law is necessary but not sufficient. Regulators need in-house capability in neuroscience, signal processing, cybersecurity and privacy law to evaluate vendor claims about anonymization and to understand where inference models may overreach. Civil society can build literacy about what neural measurement can and cannot reveal, pushing back against both hype and fatalism. An independent advisory group composed of neurologists, ethicists, technologists and lawyers can issue model clauses for consent dashboards, propose audit protocols and update standards as the science evolves. Without this interdisciplinary capacity, formal rules will lag behind practice.

A measured conclusion

Neurotechnology promises social value in accessibility, rehabilitation and communication, while creating unprecedented exposure of mental life. India already has the constitutional foundation to protect dignity and autonomy. What it lacks is a statutory and regulatory architecture calibrated to the special risks of neural data. Recognising neuro-privacy as an entitlement worthy of heightened protection, creating a high-risk personal data class that explicitly includes neural signals, mandating dynamic and discoverable consent, standardizing plain-language Neuro-Privacy Statements, integrating privacy-by-design into device review and establishing a specialist ombudsman would together make the framework real. These measures are not alarmist. They are proportionate, technically grounded and compatible with innovation. They give people meaningful control over the most intimate data a system can capture while building the trust necessary for responsible progress.

**Susmit Mukherjee is a IV Year, B.A., LL.B. (Hons.) at NALSAR University of Law, Hyderabad

**Disclaimer: The views expressed in this blog do not necessarily align with the views of the Vidhi Centre for Legal Policy.